Se connecter Inscription gratuite

180 Life Sciences Ret. sur l'équité

Quel est le Ret. sur l'équité de 180 Life Sciences?

Le Ret. sur l'équité de 180 Life Sciences Corp. est 3,043.52%

Quelle est la définition de Ret. sur l'équité?



Le rendement des capitaux propres est une mesure de la rentabilité d'une entreprise par rapport à la valeur comptable des capitaux propres. Il est calculé en divisant le résultat net de l'exercice par le total des capitaux propres.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. sur l'équité des entreprises dans Health Care secteur sur NASDAQ par rapport à 180 Life Sciences

Que fait 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Entreprises avec ret. sur l'équité similaire à 180 Life Sciences